DX5057

Asset

Oral small molecule inhibition of DUX4, the transcription factor driving FSHD pathology.

Stage
Preclinical
Modality
Small molecule
Target
DUX4
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Competitors3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets